Category: Uncategorized

Sep 30 2020

Uncategorized

Stanford researchers unravel how a common genetic deletion elevates schizophrenia risk

by Clinical Editor

No Comments

A common genetic deletion boosts the risk for schizophrenia by 30-fold. Generating nerve cells from people with the deletion has showed Stanford researchers why.

Sep 30 2020

Uncategorized

Computer model explains altered decision making in schizophrenia

by Clinical Editor

No Comments

Scientists have built a computer ‘brain circuit’, or artificial neural network, that mirrors human decision-making processes and sheds light on how circuits might be altered in psychiatric diseases, a …

Sep 29 2020

Uncategorized

Stanford scientists solve secret of nerve cells marking a form of schizophrenia – Stanford Medical Center Report

by Clinical Editor

No Comments

Stanford scientists solve secret of nerve cells marking a form of schizophrenia  Stanford Medical Center Report

Sep 29 2020

Uncategorized

Concert Pharma completes enrollment in mid-stage study of CTP-692 in schizophrenia

by Clinical Editor

No Comments

Concert Pharmaceuticals (NASDAQ:CNCE) has completed the enrollment of 325 adult subjects in a Phase 2 clinical trial evaluating CTP-692 as an adjunctive treatment for schizophrenia.

Sep 29 2020

Uncategorized

Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia

by Clinical Editor

No Comments

Concert completed enrollment in its Phase 2 trial evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia.

Sep 29 2020

Uncategorized

Stanford scientists solve secret of nerve cells marking a form of schizophrenia

by Clinical Editor

No Comments

A common genetic deletion boosts the risk for schizophrenia by 30-fold. Generating nerve cells from people with the deletion has showed Stanford researchers why.

Sep 29 2020

Uncategorized

Stanford researchers unravel how a common genetic deletion elevates schizophrenia risk

by Clinical Editor

No Comments

A common genetic deletion boosts the risk for schizophrenia by 30-fold. Generating nerve cells from people with the deletion has showed Stanford researchers why.

Sep 29 2020

Uncategorized

Alkermes: Schizophrenia Drug Producer Taking Market Share, 5.5% 3-Month Upside

by Clinical Editor

No Comments

Alkermes plc is a global biopharmaceutical company focused on developing and commercializing products related to schizophrenia, bipolar disorder, multiple sclerosis, and recently oncology.

Sep 28 2020

Uncategorized

Researchers reveal sex differences in association between symptoms of schizophrenia and superoxide dismutase

by Clinical Editor

No Comments

Schizophrenia is a disabling psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as decreased expression ability, and cognitive …

Sep 28 2020

Uncategorized

NIH to promote early intervention for schizophrenia via public-private partnership

by Clinical Editor

No Comments

The National Institutes of Health announced a new public-private partnership, the goal of which is to meet the urgent need for early therapeutic interventions for people at risk of developing...